Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Apellis Pharmaceuticals Inc APLS

Healthcare Biotechnology
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related... see more

Recent & Breaking News (NDAQ:APLS)

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 25, 2023

APLS Investors Have Opportunity to Lead Apellis Pharmaceuticals, Inc. Securities Fraud Lawsuit

PR Newswire August 25, 2023

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire August 25, 2023

APLS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Apellis Class Action Lawsuit

Business Wire August 24, 2023

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 24, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire August 24, 2023

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc.(APLS) Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire August 24, 2023

ROSEN, Top Ranked Investor Counsel, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS

Newsfile August 23, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 23, 2023

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire August 23, 2023

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS

Newsfile August 22, 2023

Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)

GlobeNewswire August 22, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

Newsfile August 22, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 22, 2023

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 - (NASDAQ: APLS)

PR Newswire August 22, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm

Accesswire August 22, 2023

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 21, 2023

APLS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile August 21, 2023

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS

Newsfile August 21, 2023

APLS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Apellis Pharmaceuticals, Inc.

Accesswire August 21, 2023